Palo Alto, CA, United States of America

Mitchell A Avery


Average Co-Inventor Count = 2.9

ph-index = 4

Forward Citations = 54(Granted Patents)


Location History:

  • Palo Alto, CA (US) (1988 - 1993)
  • Grand Forks, ND (US) (1996 - 1997)

Company Filing History:


Years Active: 1988-1997

Loading Chart...
9 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Mitchell A. Avery

Introduction

Mitchell A. Avery is a prominent inventor based in Palo Alto, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antihypercholesterolemic compounds. With a total of 9 patents to his name, Avery's work has the potential to impact the treatment of hypercholesterolemia.

Latest Patents

Avery's latest patents focus on novel antihypercholesterolemic agents. These agents are designed to treat hypercholesterolemia effectively. One of the exemplary groups of compounds he has developed features a structural formula where R is a C-17 side chain, R.sup.1 is --OH, .dbd.O, or similar, and X and Y can be CH, C--OH, C--OCH.sub.3, or C--Z. The methods of using these compounds, along with other novel oxysterol analogs, are also outlined in his patents. Pharmaceutical compositions containing these compounds are included as well.

Career Highlights

Mitchell A. Avery is associated with SRI International, a well-respected research institution. His work at SRI has allowed him to focus on innovative pharmaceutical research and development. His contributions have been instrumental in advancing the understanding and treatment of cholesterol-related health issues.

Collaborations

Avery has collaborated with notable colleagues such as Wesley K. Chong and Masato Tanabe. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Mitchell A. Avery's innovative work in the field of antihypercholesterolemic compounds showcases his dedication to improving health outcomes. His patents and collaborations reflect a commitment to advancing pharmaceutical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…